Summary Protein expression of the putative tumour-suppressor gene DCC on chromosome 18q was evaluated in a panel of 16 201. In addition, 9 out of 15 normal tissue specimens were mutated in codon 201. In two out of three cases with homozygous wild-type codons in peripheral blood lymphocyte (PBL) DNA, mutations were already observed in the tumour adjacent normal colonic mucosa. We conclude that DCC immunostaining should be introduced in the clinicopathological routine because of its strong correlation with the known prognostic markers 18q LOH and mutation of codon 201.
Genetic alterations in multistep colorectal tumorigenesis include loss of heterozygosity (LOH) of the putative tumour-suppressing DCC (deleted in colon carcinoma) gene on chromosome 18q21.1 Fearon et al, 1990; lacopetta et al, 1994) . Although allelic deletions are infrequent in early or intermediate stage adenomas, about 50% of advanced stage adenomas and more than 70% of colorectal cancer (CRC) show LOH of chromosome 18q (Vogelstein et al, 1988) . Recently, Jen et al (1995) have reported that the status of chromosome 18q has prognostic value for the clinical course and the survival of CRC patients giving patients with stage II cancer and 18q LOH a similar prognosis than patients with stage III cancer. Furthermore, 18q LOH correlates with an increased likelihood of distant metastasis (Kern et al, 1989) and is a strong predictive factor for deep muscle and lymphatic invasion (lino et al, 1994) . In more than 90% of carcinomas with 18q allelic loss the deleted region includes the DCC locus . Reduced or missing mRNA expression was observed in more than 50% of CRC (Itoh et al, 1993 ) but a general mechanism for inactivation of the remaining allele has not yet been elucidated.
The DCC gene encodes a neural cell adhesion-like transmembrane protein. Its extracellular region is composed of six immunoglobulin-like domains and four fibronectin-type III repeats. Functionally, the DCC gene product might control cell division and it might play a critical role in embryonic development and cell differentiation (Edelman and Crossin, 1991; Chuong et al, 1994; Hedrick et al, 1994) . As shown recently by Keino-Masu et al (1996) in neural tissue, DCC is a netrin receptor that is required for the guidance of developing axons. Outside the nervous system, the DCC gene is also expressed in most epithelial tissues (Reale et al, 1994) . How its tumour-suppressive effect is achieved here is still unclear. Probably, reduced or missing protein. expression might contribute to poor differentiation or increased proliferation or to metastasis through the loss of adhesiveness.
The strong prognostic value of 18q LOH for clinical course and survival of patients with CRC and the putative tumour-suppressive function of the DCC gene product (Tanaka et al, 1991) asks for the development of a method directly detecting the DCC gene product in CRC. As recently discovered by Hahn et al (1996) , another putative tumour-suppressor gene, the DPC4 gene (deleted in pancreatic cancer locus 4), has been mapped to chromosome 18q21 very near to the DCC gene locus. Therefore, further attempts on protein level are required to clarify if the DCC gene itself is causally involved in tumorigenesis as a tumour suppressor (Thiagalingam et al, 1996) . The aim of this study was to establish an immunohistochemical assay for routine use and to correlate these data with the results of the molecular genetic analysis.
MATERIALS AND METHODS
Tissue preparation and DNA/RNA extraction Tissues were obtained from 16 CRC patients by surgical resection and processed immediately after removal. After dissection of (Chomczynski and Sacchi, 1987) . DNA was also extracted from peripheral blood lymphocytes (PBLs) from some patients.
LOH analysis by polymerase chain reaction (PCR) generating a restriction fragment length polymorphism (RFLP)
The PCR-RFLP-LOH assay was carried out as described previously (Huang et al, 1992 Codon 201-mutation assay
The primers for the codon 201 mutation assay (Honsako et al, 1994 ) span a 155-bp fragment within exon 3 and the adjacent 3' intron of the DCC gene. Only amplification of the wild-type sequence with a CGA in codon 201 generates a diagnostic Sall restriction site. A 200-ng sample of genomic DNA was used in a reaction mixture (total 50 ,ul) containing each primer at 400 nM, deoxynucleotide triphosphates at 200 ,UM and 4 units of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA). Typical reaction conditions included initial denaturation for 3 min at 95°C, followed by 35 cycles of 1 min at 95°C, 1 min annealing at 65°C and 2 min extension at 72°C and a final extension step for 10 min at 72°C. The primer sequences were 201-U 5'-GTC TTG CCC TCT GGA GCA TTG CAG ATC AGT-3' and 201-D 5'-CTG AAG GCA ACA AAG AGC ATT GC-3'. After amplification, PCR products were SalI (Boehringer, Mannheim) digested and electrophoresed on a 8% polyacrylamide gel. DNA fragments were visualized under UV light by staining with ethidium bromide.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis and Southern blot analysis directly used for PCR amplification using the conditions described above but with a different annealing temperature of 550C. The PCR amplification was carried out using the antisense primer DCC-D and the sense primer DCC-U 5'-TTC CGC CAT GGT TTT TAA ATC A-3' (Fearon et al, 1990 ) generating a 233-bp PCR product (nucleotide 986 to 1218). The primers span an intron to prevent undiscerned genomic amplification. After separation on a 2% agarose gel and transfer to a nylon membrane, hybridization was performed with a 32P-labelled 57-mer-oligonucleotide spanning nucleotide 1141 to 1197 of the DCC cDNA or with a 32p_ labelled 233-bp cDNA reference fragment according to nucleotide sequence 986 to 1218 as described by Fearon et al, (1990) . Each PCR procedure was performed simultaneously with the ,B-actin primers Ac-U 5'-CCT TCC TGG GCA TGG AGT CCT-3' and Ac-D 5'-GGA GCA ATG ATC TTG ATC TT-3' generating a 202-bp fragment as control reaction. The P-actin 19-mer oligonucleotide
Ac-H 5'-GTG GAT GCC ACA GGA CTC C-3' hybridizing within the 202-bp fragment was used as positive control in Southern blot analysis (Ponte et al, 1984) .
Immunohistochemical analysis
Intensity and tissue localization of DCC protein expression were evaluated by immunohistochemistry. Cryosections (7 gm) from matched tumour and normal mucosal tissues were prepared, fixed for 20 min at 4°C in 1% paraformaldehyde and washed three times with 0.01 M phosphate-buffered saline (PBS), pH 7.4. Subsequently, they were incubated with purified murine antihuman DCC monoclonal antibody 15041A (PharMingen, San Diego, CA, USA), directed against the intracellular domain of the DCC gene produce at 2 ,ug ml-' in PBS for 45 min at room temperature in a humidified chamber. Positive and negative controls with an identical isotype (IgGI) were carried out in the same way for each tissue specimen. Incubation with the secondary horseradish peroxidase conjugated and preabsorbed anti-mouse antibody P 260 (Dako, Hamburg, Germany) was performed at 20-fold dilution in PBS including 35% immunoglobulin-free fetal calf serum for 45 min at room temperature. Specifically bound antibody was then visualized as described previously (Dippold et al, 1985) by peroxidase catalysed substrate conversion of 3-amino-9-ethylcarbazole with 0.03% hydrogen peroxide and subsequent counterstaining with haematoxylin. The intensity of cellular staining was classified as '+++' when more than 50% of the cells were stained positively;
'+', when less than 10% of the cells were stained positively; '++', when staining reactivity was between 10 and 50% and '-' when no staining was detectable in any cell.
RESULTS
In the present study, we compared 16 matched CRC and normal colonic tissue samples with genetic alterations of the DCC gene locus and DCC mRNA and protein expression.
LOH analysis
Allelic losses of the DCC gene were determined with a PCR-RFLP-LOH assay generating a PCR product with a diagnostic MspI restriction pattern. A total of 12 of the 16 (75%) cases were informative and LOH was detected in 2 out of 12 cases ( Protein expression DCC protein expression was investigated by immunohistochemistry using the commercially available monoclonal antibody 15041A directed against the intracellular domain of the DCC protein ( Figure 3 ). All normal tissue specimens exhibited an intense staining restricted to the mucosa. The most pronounced DCC expression was found in the crypts, whereas staining of the luminal surface was less intense and heterogeneous ( Figure 3A) . Goblet cells, which account for approximately 20% of the crypt epithelium, were always brightly positive. In tumour tissue no DCC expression was seen in 11 out of 16 samples corresponding to 69% of all cases ( Figure 3D ). When present in CRC, most tumour tissues showed an inhomogeneous DCC distribution pattern in these cases and DCC protein expression was higher in well-differentiated carcinomas compared with moderately and poorly differentiated ones. 
Codon 201 mutation analysis
It is believed that the retained DCC allele in patients suffering 18q LOH is inactivated by localized mutations. Given the large size of the DCC gene, only a few mutations have been identified so far and none can account for the complete loss of the DCC protein in the afflicted tissue (Cho and Fearon, 1995 (Figure 4 , Table 1 ).
DISCUSSION
The DCC gene on chromosome 1 8q is a candidate tumoursuppressor gene that was previously characterized by systematic evaluations of LOH in a series of CRC (Vogelstein et al, 1988 Fearon et al, 1990) . Evidence for a tumour-suppressive function of DCC arised from experiments by Klingelhutz et al (1993) , who have shown that it can suppress tumorigenesis when exogenously introduced into neoplastic cells lacking DCC expression. In addition, the high prevalence of 18q LOH including the DCC gene locus and its increasing frequency during colorectal tumour development from early adenomatous stages to carcinoma also argue for a tumour-suppressive function of the DCC gene (Vogelstein et al, 1988) . The presence of a functional protein in normal mucosa vs loss in malignant tissue is a prerequisite for the putative tumour-suppressive function of DCC. For a panel of gynaecological tumours Enomoto et al (1995) reported reduced or lost expression in endometrial and ovarian malignancies compared with the DCC mRNA and protein expression levels in the corresponding normal tissues. We examined DCC protein expression in a panel of matched CRC and normal colonic mucosa. To prevent cross-reactivity we used a monoclonal antibody against the non-homologous intracellular region of DCC that was not directed against the high homologous extracellular immunoglobulin-or fibronectin-like domains. As reported by Turley et al (1995) , several murine monoclonal antibodies raised against extracellular epitopes of DCC failed to detect the DCC protein in normal colonic epithelium. According to the putative tumour-suppressive function of the DCC gene produce and to former immunohistochemical results with a polyclonal rabbit anti-DCC antibody raised against the intracellular domain , an intense immunostaining should be seen in normal colonic mucosa detected by a useful anti-DCC antibody. With 15041A, we found that DCC protein expression is almost always lost in CRC, whereas the adjacent normal mucosa is brightly positive, indicating that tumorigenesis is indeed accompanied by the loss of DCC protein. In a few CRC cases, DCC protein was still detectable, but DCC immunoreactivity was mostly restricted to distinct areas. It will be of interest to determine the DCC expression in primary and metastatic tumours in these cases. Furthermore, the lower expression in only moderately or poorly differentiated CRC supports the hypothesis that the loss of DCC protein may account for the progression of colorectal tumorigenesis.
The aim of this study was to establish a DCC expression assay for routine clinical practice. Therefore, the tissue preparation procedure had to be a simple macroscopical dissection. Although we kept the contamination of our tumour specimens with normal colonic mucosa cells as low as possible, the frequencies of LOH or lost mRNA expression detected by PCR may be underestimated. We demonstrated LOH in 2 out of 12 informative cases, which is not as frequent as usually reported for colorectal carcinoma, although the published frequencies range widely from 20% to 70% (Vogelstein et al, 1988; Sasaki et al, 1989) . Compared with other studies using only a few polymorphic markers or only one PCR based LOH assay (Sasaki et al, 1989; lino et al, 1993; lacopetta et al, 1994) , our LOH frequency obtained from 16 matched tissue samples after macroscopical dissection by PCR seems quite likely. Even if we cannot exclude that some of the RT-PCR-positive tumours would be DCC mRNA negative when tissue had been prepared by time-consuming microdissection, our DCC mRNA results are in good agreement with the literature (Itoh et al, 1993) . Presently, mainly 18q LOH is used in prognostic assessments. We suggest that the measurement of DCC protein by immunohistochemistry should be introduced in the clinicopathological routine as an additional or alternative prognostic marker. It is easy to perform, not influenced by adjacent normal tissue and only needs small amounts of material.
Homozygous DCC gene deletions are restricted to a few published cases (Fearon et al, 1990; Murty et al, 1994) and were not seen in the present study. Typically, the inactivation of a tumoursuppressor gene involves the allelic deletion of one of the two parental alleles, detectable as LOH and according to Knudson (1985) this unmasks a recessive mutation in the remaining allele. A few somatically acquired point mutations in the DCC gene generating a novel splice acceptor site or nonsense or missense mutations in the coding sequence as well as insertional mutagenesis in some CRC cases have been reported (Fearon et al, 1990; Miyake et al, 1994) . But without any evidence for a general molecular mechanism leading to the inactivation of the DCC allele in CRC, the analysis of additional mutations should be pursued. Therefore, we analysed the loss of the wild-type codon 201 in CRC and adjacent normal mucosa. Miyake et al (1994) had previously identified this mutation as a 'polymorphic change' in a single case of oesophageal squamous cell carcinoma and its adjacent normal mucosa but without any data about the codon 201 sequence in PBLs or other somatic cells outside of the oesophageal mucosa. Our data indicate that the C to G transition of the first base in codon 201 is indeed a real mutation because all the three PBL samples analysed showed completely digestible wild-type codons 201, whereas the pattern of the Sall restriction hydrolysis was already different in two cases of normal colorectal mucosa compared with the corresponding PBLs. Honsako et al (1994) have found that the loss of wild-type codon 201 is significantly increased in invasive colorectal carcinomas and carcinomas with distant metastasis. Thus, the epidemiological data of 18q LOH (Kern et al, 1989; Iino et al, 1994) as well as the results of the codon 201 study (Honsako et al, 1994) appear to be predictive indicators for local invasion and distant metastasis in CRC. As shown by Jen et al (1995) 18q LOH has strong prognostic value for the outcome of CRC patients. To prove that DCC has a tumoursuppressive function in colorectal tumorigenesis the prognostic markers 1 8q LOH and loss of wild-type codon 201 have to be associated with reduced or absent expression of the DCC gene product in CRC. In fact, we could show in the present study that the DCC protein is not expressed in cases with proven LOH. In particular, DCC immunoreactivity was negative in 89% (eight out of nine) of the tumours with loss in both 201 wild-type codons whereas at least one wild-type codon 201 was present in 80% (four out of five) of the tumours with positive immunoreactivity (Table 2) . We speculate that loss of both wild-type codons 201 might interfere with the DCC transcription or translation. Although our data suggest a correlation between codon 201 and DCC protein expression, we do not believe in loss of wild-type codon 201 as the only cause for inactivation of the remaining allele. Therefore, a situation with no detectable wildtype codon 201 does not lead inevitably to a loss of DCC protein expression (patient UZ, Table 1 ). In addition, we found that the loss of the wild-type codon 201 is not restricted to CRC. It also occurs with high frequency in the adjacent normal mucosa, resulting in a heterozygous allelotype with one wild-type and one mutant codon. Upon malignant transformation, 53% of the tumours accumulate an additional loss of the retained wild-type codon, thus exhibiting a mutant phenotype with no wild-type codon 201. We speculate that the loss of the first wild-type codon 201 could be an early premalignant event in the colorectal adenoma-carcinoma-sequence. In a further study, it will be of special interest to evaluate the codon 201 status in normal colonic mucosa without any evidence for adjacent CRC and to analyse the biochemical importance of this missense mutation in exon 3 related to the inactivation of a remaining DCC allele.
